Edition:
United Kingdom

Daiichi Sankyo Announces Clinical Research Collaboration With Merck KGaA, Darmstadt, Germany And Pfizer


Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO ANNOUNCES CLINICAL RESEARCH COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY AND PFIZER TO EVALUATE FAM- TRASTUZUMAB DERUXTECAN (DS-8201) WITH AVELUMAB AND A DNA DAMAGE RESPONSE INHIBITOR IN PATIENTS WITH HER2 EXPRESSING AND MUTATED SOLID TUMORS.DAIICHI SANKYO CO LTD - ENTERED INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY AND PFIZER, INC.DAIICHI SANKYO - AGREEMENT TO EVALUATE COMBINATION OF FAM- TRASTUZUMAB DERUXTECAN WITH CHECKPOINT INHIBITOR AVELUMAB AND/OR DDR INHIBITOR.